<DOC>
	<DOCNO>NCT01899846</DOCNO>
	<brief_summary>This study evaluate level hydroxyprogesterone caproate 's metabolite blood throughout pregnancy There 3 cohort subject Cohort 1 ( 6 subject ) daily blood draw morning approximately time day one week follow first dose Makena blood drawn immediately prior 2 successive Makena dose Epoch 1 ( 24 - 28 week ) Epoch 2 ( 32 - 36 week ) Cohort 2 ( 8 subject ) blood drawn determine trough concentration 7 day first dose Makena . Subjects daily blood draw one week follow dose Makena give Epoch 1 ( 24 - 28 week ) blood drawn immediately prior 2 successive dos Epoch 2 ( 32 - 36 week ) Cohort 3 ( 16 subject ) blood drawn determine trough concentration 7 day first dose Makena . Subjects blood drawn immediately prior 2 successive dos Epoch 1 ( 24 - 28 week ) daily blood draw one week follow dose Makena give Epoch 2 ( 32 - 36 week ) A maximum 10 subject monitor select day follow completed course Makena therapy determine terminal elimination phase .</brief_summary>
	<brief_title>Pharmacokinetic Study Makena® ( Hydroxyprogesterone Caproate Injection , 250 mg/mL ) Its Metabolites Blood</brief_title>
	<detailed_description />
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>Age ≥ 18 year . Singleton gestation . Gestational age 16 week 0 day 20 week 6 day . Previous singleton spontaneous preterm delivery Multifetal gestation . Known major fetal anomaly fetal demise . Progestin treatment form 4 week prior study entry . Heparin therapy current pregnancy history thromboembolic disease . Maternal medical/obstetrical complication include hypertension require medication seizure disorder . uterine anomaly fibroid Known hypersensitivity hydroxyprogesterone caproate injection component . Any significant medical disorder , opinion investigator , would contraindication use drug would preclude accurate evaluation subject 's condition outcome compromise subject 's safety study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Makena</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Prior preterm delivery</keyword>
	<keyword>Hydroxyprogesterone Caproate</keyword>
	<keyword>17P</keyword>
</DOC>